Unknown Manufacturer
Narsoplimab is an anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
Narsoplimab is an anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
Transplant-associated thrombotic microangiopathy (TA-TMA) has complex underlying pathophysiology but generally involves complement activation associated with endothelial injury, microthrombus development, and downstream organ dysfunction. Studies have demonstrated a role for the alternative and lectin complement pathways in TMA. Within the lectin pathway, considerable interest has fallen on the effector protein mannan-associated lectin-binding serine protease-2 (MASP-2), which cleaves C4 and C2 to form the C3 convertase C4bC2a. Narsoplimab, a human IgG4λ anti-MASP-2 antibody, appears effective in limiting lectin pathway-associated microvascular activation/injury in TA-TMA, presumably by directly inhibiting the formation of C4bC2a.
